Literature DB >> 22151896

Recent trend of clinical features in patients with hepatocellular carcinoma.

Yuko Nagaoki1, Hideyuki Hyogo, Hiroshi Aikata, Mio Tanaka, Noriaki Naeshiro, Takashi Nakahara, Yoji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Kazuaki Chayama.   

Abstract

AIM: In this study, we evaluated the clinical characteristics of hepatocellular carcinoma (HCC) because the etiology of HCC has been changing recently.
METHODS: Consecutive 1374 HCC patients at our institution from 1995 to 2009 were enrolled and clinical characteristics were investigated.
RESULTS: Seventeen percent and 67% of HCC were related to hepatitis B virus (HBV-HCC) and hepatitis C virus (HCV-HCC), respectively. Fifteen percent of that was negative for hepatitis B surface antigen (HBsAg) and antibody to hepatitis C virus (HCVAb) (NBNC-HCC). HCV-HCC tended to decrease and NBNC-HCC tended to increase in recent years. Patients with NBNC-HCC and HCV-HCC were significantly older than those with HBV-HCC. The complication rates of diabetes mellitus (DM), heavy alcohol consumption, hypertension, and hyperlipidemia in NBNC-HCC were significantly higher than those in other groups. Furthermore, the platelet counts and body mass index in NBNC-HCC were significantly higher than those of other groups. Among 209 NBNC-HCC patients, 58 patients underwent hepatic resection in which 29%, 36%, and 35% of those were based on non-alcoholic steatohepatitis (NASH), heavy alcohol consumption, and unknown etiology, respectively. DM was prevalent especially in NASH and heavy alcohol consumption. Cirrhosis was detected in 65%, 81%, and 15% in NASH-HCC, heavy alcohol consumption-HCC, and unknown etiology, respectively.
CONCLUSIONS: NBNC-HCC has gradually been increasing in recent years. The present study elucidated that the presence of NASH and metabolic syndrome were important risk factors for NBNC-HCC and suggests that these patients should receive surveillance for HCC development.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 22151896     DOI: 10.1111/j.1872-034X.2011.00929.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  40 in total

1.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

2.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

Review 3.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

4.  Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Authors:  Yoshihiro Mikuriya; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Tomoyuki Abe; Masakazu Hashimoto; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2015-03-06       Impact factor: 3.445

5.  microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma.

Authors:  Wei-Hua Song; Xiao-Jun Feng; Shao-Juan Gong; Jian-Ming Chen; Shou-Mei Wang; Dong-Juan Xing; Ming-Hua Zhu; Shu-Hui Zhang; Ai-Min Xu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Decreased expression of hsa_circ_0003570 in hepatocellular carcinoma and its clinical significance.

Authors:  Liyun Fu; Shengdong Wu; Ting Yao; Qingqing Chen; Yi Xie; Sheng Ying; Zhigang Chen; Bingxiu Xiao; Yaoren Hu
Journal:  J Clin Lab Anal       Date:  2017-05-11       Impact factor: 2.352

7.  Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma.

Authors:  Hiroya Iida; Tsukasa Aihara; Shinichi Ikuta; Naoki Yamanaka
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

Review 8.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 9.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

10.  Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.

Authors:  Shao-Juan Gong; Xiao-Jun Feng; Wei-Hua Song; Jian-Ming Chen; Shou-Mei Wang; Dong-Juan Xing; Ming-Hua Zhu; Shu-Hui Zhang; Ai-Min Xu
Journal:  Cancer Biol Ther       Date:  2015-11-30       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.